Investor Conference Call Details - 24 April 2013
Release Date: 23/04/2013 12:00am
Pharmaxis Ltd (PXS) expects to complete its analysis and announce the results of its Phase III clinical trial of Bronchitol in patients with bronchiectasis prior to opening of the market tomorrow, 24 April 2013. The announcement will have the effect of lifting the current trading halt over the company’s shares.
The company will hold an investor teleconference at 9.30am tomorrow to discuss the results.
Telephone access (toll free):
- Australia: 1800 059 809 or 1800 606 599
- USA/Canada: 1855 881 1339
- UK: 0800 051 8245
- NZ: 0800 453 055
Telephone access (metered): +61 2 9008 9005
Online access: http://services.choruscall.com/links/pharmaxis130424.html
A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.
Categories: News and Media